Chronic anticoagulation in non-valvular atrial fibrillation: Where things stand

Kareem Bedeir; Robert P. Giugliano; Basel Ramlawi

doi:10.1016/j.ijcard.2016.07.271

Chronic anticoagulation in non-valvular atrial fibrillation: Where things stand

Kareem Bedeir, Robert P. Giugliano, Basel Ramlawi

Academic Institute

Research output: Contribution to journal › Review article

4 Scopus citations

Abstract

One in every five strokes is due to atrial fibrillation. Anticoagulation is the evidence-based practice for stroke risk reduction in patients with atrial fibrillation. After decades of using warfarin, the recent years have seen an exponential increase in the available oral anticoagulants. An understanding of where things stand regarding indications, relative safety and efficacy as well as the limitations of each available choice is crucial.

Original language	English (US)
Pages (from-to)	615-619
Number of pages	5
Journal	International Journal of Cardiology
Volume	222
DOIs	https://doi.org/10.1016/j.ijcard.2016.07.271
State	Published - Nov 1 2016

Keywords

Atrial fibrillation
Bleeding prevention
Stroke

ASJC Scopus subject areas

Medicine(all)
Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.ijcard.2016.07.271

Fingerprint Dive into the research topics of 'Chronic anticoagulation in non-valvular atrial fibrillation: Where things stand'. Together they form a unique fingerprint.

Cite this

@article{6cb0a750dd014b09adc30435d1f117a2,

title = "Chronic anticoagulation in non-valvular atrial fibrillation: Where things stand",

abstract = "One in every five strokes is due to atrial fibrillation. Anticoagulation is the evidence-based practice for stroke risk reduction in patients with atrial fibrillation. After decades of using warfarin, the recent years have seen an exponential increase in the available oral anticoagulants. An understanding of where things stand regarding indications, relative safety and efficacy as well as the limitations of each available choice is crucial.",

keywords = "Atrial fibrillation, Bleeding prevention, Stroke",

author = "Kareem Bedeir and Giugliano, {Robert P.} and Basel Ramlawi",

year = "2016",

month = nov,

day = "1",

doi = "10.1016/j.ijcard.2016.07.271",

language = "English (US)",

volume = "222",

pages = "615--619",

journal = "International Journal of Cardiology",

issn = "0167-5273",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Chronic anticoagulation in non-valvular atrial fibrillation

T2 - Where things stand

AU - Bedeir, Kareem

AU - Giugliano, Robert P.

AU - Ramlawi, Basel

PY - 2016/11/1

Y1 - 2016/11/1

N2 - One in every five strokes is due to atrial fibrillation. Anticoagulation is the evidence-based practice for stroke risk reduction in patients with atrial fibrillation. After decades of using warfarin, the recent years have seen an exponential increase in the available oral anticoagulants. An understanding of where things stand regarding indications, relative safety and efficacy as well as the limitations of each available choice is crucial.

AB - One in every five strokes is due to atrial fibrillation. Anticoagulation is the evidence-based practice for stroke risk reduction in patients with atrial fibrillation. After decades of using warfarin, the recent years have seen an exponential increase in the available oral anticoagulants. An understanding of where things stand regarding indications, relative safety and efficacy as well as the limitations of each available choice is crucial.

KW - Atrial fibrillation

KW - Bleeding prevention

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=84981185426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981185426&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2016.07.271

DO - 10.1016/j.ijcard.2016.07.271

M3 - Review article

AN - SCOPUS:84981185426

VL - 222

SP - 615

EP - 619

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -